Form D · Pharmaceuticals
PRECIGEN, INC.
Germantown, MD · CIK 0001356090
Offering snapshot reported Dec 17, 2020 · SEC filing
- Reported sold
- $13M Offering amount: $13M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 2, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 17, 2020 | Initial | $13,000,000 | No comparison | 2 | SEC filing |
| Feb 11, 2020 | Initial | $35,000,000 | No comparison | 1 | SEC filing |
| Mar 9, 2016 | Initial | $4,250,000 | No comparison | 2 | SEC filing |
| Sep 21, 2015 | Initial | $21,585,401 | No comparison | 20 | SEC filing |
| Mar 11, 2015 | Initial | $450,015 | No comparison | 1 | SEC filing |
| Mar 9, 2015 | Initial | $10,196,546 | No comparison | 78 | SEC filing |
| Jan 28, 2015 | Initial | $57,500,000 | No comparison | 1 | SEC filing |
| Aug 22, 2014 | Initial | $28,634,166 | No comparison | 5 | SEC filing |
| Apr 10, 2014 | Initial | $24,999,943 | No comparison | 5 | SEC filing |
| May 15, 2013 | Amendment | $150,000,000 | $85,590,658vs Mar 18, 2013 | 82 | SEC filing |
| Mar 18, 2013 | Initial | $64,409,342 | No comparison | 57 | SEC filing |
| Nov 15, 2012 | Initial | $25,000,002 | No comparison | 16 | SEC filing |
| Apr 26, 2012 | Amendment | $75,000,006 | $25,000,003vs Jan 24, 2012 | 81 | SEC filing |
| Jan 24, 2012 | Amendment | $50,000,003 | $33,000,003vs Jan 9, 2012 | 42 | SEC filing |
| Jan 9, 2012 | Initial | $17,000,000 | No comparison | 2 | SEC filing |
| Nov 14, 2011 | Initial | $1,092,344 | No comparison | 17 | SEC filing |
| Sep 14, 2011 | Initial | $17,000,004 | No comparison | 1 | SEC filing |
| Jun 8, 2011 | Initial | $91,825,055 | No comparison | 58 | SEC filing |
| May 11, 2011 | Initial | $550,001 | No comparison | 1 | SEC filing |
| Apr 22, 2011 | Amendment | $66,936,470 | $49,532,569vs Mar 5, 2010 | 82 | SEC filing |
| Feb 18, 2011 | Amendment | $55,953,968 | $38,550,067vs Mar 5, 2010 | 82 | SEC filing |
| Feb 9, 2011 | Initial | $1,013,625 | No comparison | 3 | SEC filing |
| Nov 12, 2010 | Amendment | $37,506,714 | $20,102,813vs Mar 5, 2010 | 65 | SEC filing |
| Mar 5, 2010 | Initial | $17,403,901 | No comparison | 40 | SEC filing |
| Jan 5, 2010 | Initial | $25,000,000 | No comparison | 2 | SEC filing |
| Jun 29, 2009 | Initial | $9,999,999 | No comparison | 1 | SEC filing |
| Apr 24, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| May 30, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Sep 12, 2006 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Mar 9, 2006 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-383598
Consideration consisted of termination of collaborations with entities affiliated with the investors, reversion of related technology rights to the issuer, and transfer to the issuer of ownership in a joint venture formed to utilize issuer technology.
Source: Form D, filed Dec 17, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Cesar L. Alvarez | Director |
| Robert P. Beech | Executive |
| Jack A. Bobo | Executive |
| Samuel Broder | Executive |
| Sunil Chada | Executive |
| Grace E. Colon | Executive |
| Ena Chan Cratsenburg | Executive |
| Matthew B. Crisp | Executive |
| Matt Crisp | Executive |
| Steven Frank | Director |
| Gregory I. Frost | Executive |
| Tom Goralski | Executive |
| Vinita D. Gupta | Director |
| Fred Hassan | Director |
| Ronald B. Herberman | Executive |
| Larry D. Horner | Director |
| Kelly Huang | Executive |
| Corey Huck | Executive |
| Olivier R. Jarry | Executive |
| Timothy D. Kasbe | Executive |
| Thomas R. Kasser | Executive |
| Jeffrey B. Kindler | Director |
| Randal J. Kirk | Director |
| Krish S. Krishnan | Executive |
| Suma M. Krishnan | Executive |
| Donald P. Lehr | Executive |
| Joel D. Liffman | Executive |
| Joel D. Liffmann | Executive |
| Nick Macris | Executive |
| Dean J. Mitchell | Director |
| Glenn Nedwin | Executive |
| Nir Nimrodi | Executive |
| Jeffrey Perez | Executive |
| Marcelo Quiroga | Executive |
| Thomas D. Reed | Executive |
| Thomas Reed, Ph.D. | Executive |
| Jayson M. Rieger | Executive |
| Helen Sabzevari, Ph.D. | Director, Executive |
| Robert B. Shapiro | Director |
| Burton Sobel | Director |
| Rick L. Sterling | Executive |
| James S. Turley | Director |
| Joseph L. Vaillancourt | Executive |
| Robert F. Walsh, Iii | Executive |
| Darryl Webster | Executive |
| David J. Zaccardi | Director |
| Gerardo A. Zapata | Executive |
| Saiid Zarrabian | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
20374 Seneca Meadows Parkway
Germantown, MD, 20876
Germantown, MD, 20876